Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606752 | 0.88 | TYR (0.38) | TYRCNR1CNR2COMTNOTUM | |
| SCHEMBL2115662 | 0.78 | TYR (0.47) | TYRCOMT | |
| SCHEMBL2118259 | 0.74 | COMT (0.33) | COMT | |
| SCHEMBL2118143 | 0.74 | TYR (0.37) | TYRCOMT | |
| SCHEMBL2117658 | 0.68 | APP (0.41) | TYRCOMT | |
| SCHEMBL12249856 | 0.66 | COMT (0.37) | COMT | |
| SCHEMBL13555565 | 0.64 | TYR (0.39) | TYRCOMT | |
| SCHEMBL12949928 | 0.61 | TYR (0.60) | TYRCOMT | |
| SCHEMBL2187620 | 0.60 | GRM2 (0.52) | — | |
| SCHEMBL1039375 | 0.59 | PI4KA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | claimed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | claimed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | claimed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | claimed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | TYR 1743/4885CNR1 4158/4885CNR2 4472/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | TYR 1743/4885CNR1 4158/4885CNR2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.